Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
First publishedAug 7, 10:00 UTC
Last updatedAug 7, 12:39 UTC · 6m ago
1 outlet
NPR Health
1 outlets over time — hover a bar for its window & outletslast updated
Answer
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.(Image credit: Fred Tanneau)
Reported by 1 outlet — NPR Health. See all sources ↓
Read the full report at NPR Health ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
In brief
- What's the story?
- Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.(Image credit: Fred Tanneau)
- How widely is it covered?
- 1 outlet, average source rating 8.0/10.
- When was it last updated?
- 6m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Sources1TypeCoverage
Related in the knowledge graph
organizationBut KalshiorganizationFred TanneauorganizationImageorganizationKalshiorganizationPolymarketorganizationResearchers
Sources (1)
Avg source rating 8.0/10Processing cluster
A1A2A3B1B2B3